US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Respiratory/Pulmonary Market Research Reports & Industry Analysis

RSS Feeds

Respiratory/Pulmonary Industry Research & Market Reports

1    3    5  6  7  8  9  10  
Chronic Obstructive Pulmonary Disease (COPD)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... the globe. A key objective of the Chronic Obstructive Pulmonary Disease (COPD) Report is to understand the market and pipeline status of the drugs around the Chronic Obstructive Pulmonary Disease (COPD) to explore the generic ...  |  read more...
USD 2,000
Community Acquired Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... A key objective of the Community Acquired Pneumonia Report is to understand the market and pipeline status of the drugs around the Community Acquired Pneumonia to explore the generic development opportunities, licensing opportunities and to ...  |  read more...
USD 2,000
Pulmonary Arterial Hypertension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... A key objective of the Pulmonary Arterial Hypertension Report is to understand the market and pipeline status of the drugs around the Pulmonary Arterial Hypertension to explore the generic development opportunities, licensing opportunities and to ...  |  read more...
USD 2,000
Respiratory Tract Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... A key objective of the Respiratory Tract Infections Report is to understand the market and pipeline status of the drugs around the Respiratory Tract Infections to explore the generic development opportunities, licensing opportunities and to ...  |  read more...
USD 2,000
Upper Respiratory Tract Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... globe. A key objective of the Upper Respiratory Tract Infections Report is to understand the market and pipeline status of the drugs around the Upper Respiratory Tract Infections to explore the generic development opportunities, licensing ...  |  read more...
USD 2,000
Community-Acquired Bacterial Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... A key objective of the Community-Acquired Bacterial Pneumonia Report is to understand the market and pipeline status of the drugs around the Community-Acquired Bacterial Pneumonia to explore the generic development opportunities, licensing opportunities and to ...  |  read more...
USD 2,000
Cystic Fibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... key objective of the Cystic Fibrosis Report is to understand the market and pipeline status of the drugs around the Cystic Fibrosis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage ...  |  read more...
USD 2,000
Emphysema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... objective of the Emphysema Report is to understand the market and pipeline status of the drugs around the Emphysema to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline ...  |  read more...
USD 2,000
Pneumocystis Carinii Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... A key objective of the Pneumocystis Carinii Pneumonia Report is to understand the market and pipeline status of the drugs around the Pneumocystis Carinii Pneumonia to explore the generic development opportunities, licensing opportunities and to ...  |  read more...
USD 2,000
Pulmonary Fibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... key objective of the Pulmonary Fibrosis Report is to understand the market and pipeline status of the drugs around the Pulmonary Fibrosis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage ...  |  read more...
USD 2,000
Pulmonary Hypertension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... key objective of the Pulmonary Hypertension Report is to understand the market and pipeline status of the drugs around the Pulmonary Hypertension to explore the generic development opportunities, licensing opportunities and to gain competitive advantage ...  |  read more...
USD 2,000
Pulmonary Tuberculosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... key objective of the Pulmonary Tuberculosis Report is to understand the market and pipeline status of the drugs around the Pulmonary Tuberculosis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage ...  |  read more...
USD 2,000
Respiratory Syncytial Virus (RSV) Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
1/1/2016 | published by: DelveInsight
... the globe. A key objective of the Respiratory Syncytial Virus (RSV) Infections Report is to understand the market and pipeline status of the drugs around the Respiratory Syncytial Virus (RSV) Infections to explore the generic ...  |  read more...
USD 2,000
Bacterial Pneumonia-Pipeline Insights, 2016
1/1/2016 | published by: DelveInsight
... development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA ...  |  read more...
USD 1,250
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015
11/25/2015 | published by: Global Markets Direct
... therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of ...  |  read more...
USD 2,000
EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
12/1/2015 | published by: GlobalData
... of breath, wheezing, chest tightness, and other respiratory symptoms that progress over time. The disease is often caused by smoking; however, long-term exposure to other lung irritants, such as pollution, smoke from vehicle emissions and ...  |  read more...
USD 3,995
Pulmonary Hypertension - Pipeline Review, H2 2015
11/30/2015 | published by: Global Markets Direct
... therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
2016 Germany Respiratory Diseases Diagnostic Testing Market: Supplier Shares and Country Forecasts
11/16/2015 | published by: VPGMarketResearch.com
... report provides test volume and sales projections for Hospitals and Commercial/Private Labs. In addition to market share and sales forecasts, the report: - Examines market applications of Molecular Diagnostics,Monoclonal Antibodies, Immunoassays, IT and other emerging ...  |  read more...
USD 1,950
2016 Italy Respiratory Diseases Diagnostic Testing Market: Supplier Shares and Country Forecasts
11/16/2015 | published by: VPGMarketResearch.com
... report provides test volume and sales projections for Hospitals and Commercial/Private Labs. In addition to market share and sales forecasts, the report: - Examines market applications of Molecular Diagnostics,Monoclonal Antibodies, Immunoassays, IT and other emerging ...  |  read more...
USD 1,950
2016 Spain Respiratory Diseases Diagnostic Testing Market: Supplier Shares and Country Forecasts
11/16/2015 | published by: VPGMarketResearch.com
... report provides test volume and sales projections for Hospitals and Commercial/Private Labs. In addition to market share and sales forecasts, the report: - Examines market applications of Molecular Diagnostics,Monoclonal Antibodies, Immunoassays, IT and other emerging ...  |  read more...
USD 1,950
2016 U.K. Respiratory Diseases Diagnostic Testing Market: Supplier Shares and Country Forecasts
11/16/2015 | published by: VPGMarketResearch.com
... report provides test volume and sales projections for Hospitals, Commercial and Public Health Labs. In addition to market share and sales forecasts, the report: - Examines market applications of Molecular Diagnostics,Monoclonal Antibodies, Immunoassays, IT and ...  |  read more...
USD 1,950
2016 Japan Respiratory Diseases Diagnostic Testing Market: Supplier Shares and Country Forecasts
11/16/2015 | published by: VPGMarketResearch.com
... report provides test volume and sales projections for Hospitals and Commercial/Private Labs. In addition to market share and sales forecasts, the report: - Examines market applications of Molecular Diagnostics,Monoclonal Antibodies, Immunoassays, IT and other emerging ...  |  read more...
USD 2,400
2016 U.S. Respiratory Diseases Diagnostic Testing Market: Supplier Shares and Country Forecasts
11/16/2015 | published by: VPGMarketResearch.com
... report provides test volume and sales projections for Hospitals, Physician Offices, Commercial, and Public Health Labs. In addition to market share and sales forecasts, the report: - Examines market applications of Molecular Diagnostics,Monoclonal Antibodies, Immunoassays, ...  |  read more...
USD 3,600
COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands
11/13/2015 | published by: GBI Research
... inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of death in the world. COPD ...  |  read more...
USD 4,995
Lung Infections Global Clinical Trials Review, H2, 2015
11/25/2015 | published by: GlobalData
... line data relating to the clinical trials on Lung Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical ...  |  read more...
USD 2,500
1    3    5  6  7  8  9  10